On October 21, 2026 Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics ("Molecular Partners" or the "Company"), reported the selection of MP0730 as its lead Radio-DARPin candidate targeting the tumor-associated antigen CD70. MP0730 is the third program in the Company’s pipeline of targeted alpha radiotherapeutics, and a first-in-human program is expected to start mid-2027.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Molecular Partners presented preclinical data on MP0730 at the Discovery on Target – Radioligand Therapies conference on October 1, 2026, in Boston, MA (presentation title: DARPins as Ligands for Targeted Alpha Therapy: First-in-Human Experience with MP0712 and Opportunities for Next Radio-DARPin Candidates). The data outline an attractive biodistribution profile of the CD70-targeting Radio-DARPin lead candidate in tumor-bearing mice, with strong and sustained tumor uptake relative to healthy tissues, including kidney, liver and blood.
"The selection of MP0730 as our third Radio-DARPin Therapeutic marks another important milestone in our ambition to deliver transformative therapies for patients with high unmet medical needs. CD70’s clean expression profile paired with MP0730’s best-in-class properties provide a compelling foundation for achieving a favorable therapeutic index, addressing on-target, off-tumor accumulation observed with certain radiopharmaceutical approaches against other antigens expressed in kidney cancer," said Daniel Steiner, Ph.D., SVP Targeted Radiotherapeutics of Molecular Partners.
CD70 is a clinically validated target, demonstrated through CAR-T cell therapies, and is overexpressed in clear cell renal cell carcinoma (ccRCC), a type of kidney cancer, and in other cancer indications. CD70 expression is maintained in metastases and limited in healthy tissues, making it an ideal candidate for targeted alpha radiotherapy.
ccRCC has a robust DNA repair mechanism and is inherently resistant to conventional cytotoxic therapies. Targeted alpha therapy induces difficult-to-repair double-strand breaks in tumor cells, independently from genetic mutations, due to its high linear energy transfer, thereby offering a new avenue for patients with hard-to-treat cancers such as ccRCC.
(Press release, Molecular Partners, OCT 21, 2026, View Source [SID1234673645])